Motilal Oswal Recommends Buying Emcure Pharmaceuticals, Sets Rs 2,330 Target
Motilal Oswal cited recovery in Emcure’s domestic formulation segment, led by gynecology, anti-infectives, cardiac and anti-diabetic products, and strong growth in key brands.